Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022

Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
share Share

New Affirm® Contrast Biopsy Technology Included in the Screening, Diagnosis, Treatment and Monitoring Solutions on Display

Hologic, will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec.1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.

“As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and we’re eager to engage with industry leaders at this year’s RSNA meeting to share our vision for the future of breast health,” said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. “We are equally excited to showcase our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients in action.”

Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View® Contrast-Enhanced Mammography software. The contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which historically has been used to find and biopsy more elusive lesions, such as those that cannot be seen via mammography or ultrasound. While breast MRI can be time-consuming and costly, contrast technology gives radiologists another option in the mammography suite that addresses these shortcomings.1,2 In a recent clinical study, 98% of patients had an overall positive opinion of their procedure experience with Affirm Contrast Biopsy software.3

RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 at McCormick Place in Chicago. In addition to the AffirmContrast Biopsy software, Hologic will feature its Dimensions® mammography portfolio and Supersonic® MACH™ ultrasound systems.

Hologic will also host a series of CME- and non-CME-accredited medical education symposiums and learning opportunities, accessible to attendees on-site and from remote locations. The medical education sessions include:

  • “Upright Biopsy with Brevera® Breast Biopsy System: Real-Time Imaging, Verification & Automated Handling”
    Sunday, Nov. 27: 11:45 a.m. – 12:45 p.m. CST
    Dr. Krystal Airola will demonstrate new upright breast biopsy technologies that will enhance accuracy, workflow and patient experience. She will share her experiences with the Affirm 2D/3D upright biopsy, lateral arm approach and Brevera Breast Biopsy system, which integrates tissue acquisition, real-time imaging and verification, and post-biopsy sample handling. Dr. Airola will also share cases and explain how to significantly reduce the time and discomfort to patients in the biopsy suite while maximizing biopsy suite efficiencies and clinical decision-making.

  • “Emerging Ultrasound Technology in Liver Surveillance”
    Monday, Nov. 28: 12:00 p.m. – 1:00 p.m. CST
    Learn more about the advancements in ultrasound technology with ShearWave™ Elastography. There are many opportunities to improve workflow efficiencies in liver surveillance that drive superior patient experiences and outcomes. In this lecture, participants will review comparisons with existing and emerging ultrasound technologies and techniques.

  • “Current AI Applications in Mammography: Focus on Genius AI™ Detection Software”
    Tuesday, Nov. 29: 12:00 p.m. – 1:00 p.m. CST
    Attendees will hear from an expert on the benefits of artificial intelligence (AI) in mammography screening. With new high-resolution technologies being implemented, see how AI can reduce dose, file size and reading times. A focus will be on deep-learning AI and the benefits of Genius AI Detection software in clinical decision-making and increasing productivity.

  • “Panel Discussion: Options in Localization”
    Wednesday, Nov. 30: 12:00 p.m. – 1:00 p.m. CST
    Join a multidisciplinary conversation on localization. Hear perspectives from leading radiologists and breast surgeons about what they like, what they use and why. What is the role of wires? What other technologies are available? What are the strengths and weaknesses of different options?

Source: Hologic

«« Study Finds Women with Benign Breast Disease Face Long-Term Risk of Breast Cancer

Experts Discuss Whether Supplemental Breast Cancer Screening Applies to All Women »»


1Publication for reference: Kaur, Piccolo, Arasaratnam. Implementation of Contrast-Enhanced Mammography in Clinical Practice, chapter 7, Nori, Kaur (eds.), Contrast-Enhanced Digital Mammography (CEDM). Springer, 2018.

2Hobbs MM, Taylor DB, Buzynski S, and Peake RE. Contrast-enhanced spectral mammography (CESM) and contrast MRI (CEMRI): Patient preferences and tolerance. Journal of Medical Imaging and Radiation Oncology. 2015;59:300-305

3Hologic clinical study CSR-00266 Rev 001 2022

Published on : Fri, 25 Nov 2022

Related Articles

A population-based study, involving 7778,306 women aged 50-69 years, assesses their risk of breast cancer after participating... Read more

Global Leader in Women’s Health Recognized with Three IMV ServiceTrak™ Awards for Mammography During RSNA 2022 Hologic... Read more

Ovarian cancer has the fifth highest cancer death rate among women, causing more deaths than any other cancer of the female reproductive... Read more

Mammography, Hologic, breast screening, womens health care, Brevera Breast Biopsy system Hologic, will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec.1.

No comment

Please login to leave a comment...

Highlighted Products